9 research outputs found
Effects of TNFα receptor TNF-Rp55- or TNF-Rp75- deficiency on corneal neovascularization and lymphangiogenesis in the mouse
Tumor necrosis factor (TNF)α is an inflammatory cytokine likely to be involved in the process of corneal inflammation and neovascularization. In the present study we evaluate the role of the two receptors, TNF-receptor (TNF-R)p55 and TNF-Rp75, in the mouse model of suture-induced corneal neovascularization and lymphangiogenesis. Corneal neovascularization and lymphangiogenesis were induced by three 11–0 intrastromal corneal sutures in wild-type (WT) C57BL/6J mice and TNF-Rp55-deficient (TNF-Rp55d) and TNF-Rp75-deficient (TNF-Rp75d) mice. The mRNA expression of VEGF-A, VEGF-C, Lyve-1 and TNFα and its receptors was quantified by qPCR. The area covered with blood- or lymphatic vessels, respectively, was analyzed by immunohistochemistry of corneal flatmounts. Expression and localization of TNFα and its receptors was assessed by immunohistochemistry of sagittal sections and Western Blot. Both receptors are expressed in the murine cornea and are not differentially regulated by the genetic alteration. Both TNF-Rp55d and TNF-Rp75d mice showed a decrease in vascularized area compared to wild-type mice 14 days after suture treatment. After 21 days there were no differences detectable between the groups. The number of VEGF-A-expressing macrophages did not differ when comparing WT to TNF-Rp55d and TNF-Rp75d. The mRNA expression of lymphangiogenic markers VEGF-C or LYVE-1 does not increase after suture in all 3 groups and lymphangiogenesis showed a delayed effect only for TNF-Rp75d. TNFα mRNA and protein expression increased after suture treatment but showed no difference between the three groups. In the suture-induced mouse model, TNFα and its ligands TNF-Rp55 and TNF-Rp75 do not play a significant role in the pathogenesis of neovascularisation and lymphangiogenesis
Retrospective, controlled observational case study of patients with central retinal vein occlusion and initially low visual acuity treated with an intravitreal dexamethasone implant
Background Patients with initially low visual acuity were excluded from the
therapy approval studies for retinal vein occlusion. But up to 28 % of
patients presenting with central retinal vein occlusion have a baseline BCVA
of less than 34 ETDRS letters (0.1). The purpose of our study was to assess
visual acuity and central retinal thickness in patients suffering from central
retinal vein occlusion and low visual acuity (<0.1) in comparison to patients
with visual acuity (≥0.1) treated with Dexamethasone implant 0.7 mg for
macular edema. Methods Retrospective, controlled observational case study of
30 eyes with macular edema secondary to central retinal vein occlusion, which
were treated with a dexamethasone implantation. Visual acuity, central retinal
thickness and intraocular pressure were measured monthly. Analyses were
performed separately for eyes with visual acuity <0.1 and ≥0.1. Results Two
months post intervention, visual acuity improved only marginally from 0.05 to
0.07 (1 month; p = 0,065) and to 0.08 (2 months; p = 0,2) in patients with low
visual acuity as compared to patients with visual acuity ≥0.1 with an
improvement from 0.33 to 0.47 (1 month; p = 0,005) and to 0.49 (2 months; p =
0,003). The central retinal thickness, however, was reduced in both groups,
falling from 694 to 344 μm (1 month; p = 0.003,) to 361 μm (2 months; p =
0,002) and to 415 μm (3 months; p = 0,004) in the low visual acuity group and
from 634 to 315 μm (1 month; p < 0,001) and to 343 μm (2 months; p = 0,001) in
the visual acuity group ≥0.1. Absence of visual acuity improvement was related
to macular ischemia. Conclusions In patients with central retinal vein
occlusion and initially low visual acuity, a dexamethasone implantation can
lead to an important reduction of central retinal thickness but may be of
limited use to increase visual acuity
Interleukin-2 receptor and angiotensin-converting enzyme as markers for ocular sarcoidosis
PURPOSE: To study the impact of soluble IL2 receptor (sIL2R), chest x-ray (CxR), and angiotensin-converting enzyme (ACE) as markers for sarcoidosis in uveitis patients. DESIGN: Retrospective study. METHODS: Serum concentrations of sIL2R and ACE were measured in patients with active uveitis. Those with elevated sIL2R and /or ACE values were examined for suspected systemic sarcoidosis. MAIN OUTCOME MEASURE: Our main outcome parameters were the specificity and sensitivity of sIL2R, CxR and ACE in screening for ocular sarcoidosis. RESULTS: We measured 261 patients with uveitis for sarcoidosis using sIL2R and ACE between January 2008 and November 2011; sarcoidosis was been diagnosed using other tests (e.g. computer tomography, brochoalveolar lavage, biopsy) in 41 of 53 patients with elevated sIL2R values (>639 U/ml) and in one patient with normal sIL2R (582 U/ml). Their mean sIL2R value was 1310 U/ml, extending from 582 to 8659 U/ml. Only 9 patients, however, presented elevated ACE (>82 U/l). Their mean ACE value was 116.4 U/l, ranging from 84.1 to 175.5 U/l. IL2R specificity was 94% with 98% sensitivity. In contrast, ACE had a specificity of 99.5%, but a sensitivity of only 22%; the chest x-ray had a specificity of 100% with 50% sensitivity in detecting sarcoidosis. We observed the entire spectrum of uveitis: sixteen patients suffered from anterior, 8 from intermediate, 16 from posterior, and 2 from panuveitis. CONCLUSIONS: An elevated level of soluble IL2R suggests sarcoidosis with uveitis more convincingly than ACE, making sIL2R a more effective marker parameter for sarcoidosis than ACE or chest x-ray in uveitis patients
Soluble IL2R levels (a) (p < 0.0001) and ACE levels (b) (p < 0.001) for controls (all uveitis patients/no sarcoidosis) and sarcoidosis patients with uveitis (S1 Dataset).
<p>Soluble IL2R levels (a) (p < 0.0001) and ACE levels (b) (p < 0.001) for controls (all uveitis patients/no sarcoidosis) and sarcoidosis patients with uveitis (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0147258#pone.0147258.s001" target="_blank">S1 Dataset</a>).</p
Molecular basis of the functional podocin-nephrin complex:mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains
Hereditary nephrotic syndrome is a heterogeneous disease, characterized by heavy proteinuria and renal failure. Mutations of NPHS1 or NPHS2, the genes encoding for nephrin and podocin, lead to early onset of heavy proteinuria, and rapid progression to end-stage renal disease, suggesting that both proteins are essential for the integrity of the glomerular filter. Podocin is a stomatin protein family member with a predicted hairpin-like structure localizing to the insertion site of the slit diaphragm of podocytes, the visceral glomerular epithelial cells of the kidney. Here we investigate the pathomechanisms of different disease-causing podocin mutations. We show that wild-type podocin is targeted to the plasma membrane, and forms homo-oligomers involving the carboxy and amino terminal cytoplasmic domains. The association of podocin with specialized lipid raft microdomains of the plasma membrane was a prerequisite for recruitment of nephrin into rafts. In contrast, disease-causing mutations of podocin (R138Q and R138X) failed to recruit nephrin into rafts either because these mutants were retained in the endoplasmic reticulum (R138Q), or because they failed to associate with rafts (R138X) despite their presence in the plasma membrane. None of the mutants did augment nephrin signaling, suggesting that lipid raft targeting facilitates nephrin signaling. Our findings demonstrate that the failure of mutant podocin to recruit nephrin into lipid rafts may be essential for the pathogenesis of NPHS2